NCT02921685View on ClinicalTrials.gov

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

May 28, 2019

Study Completion Date

April 28, 2020

Conditions
Hematologic Malignancies
Interventions
DRUG

Monalizumab

Four dose levels will be tested.

Trial Locations (1)

13009

RECRUITING

Institut Paoli Calmettes, Marseille

Sponsors

Collaborators (1)

Innate Pharma
All Listed Sponsors
collaborator

Innate Pharma

INDUSTRY

lead

Institut Paoli-Calmettes

OTHER